Integration of Metabolomics, Lipidomics, and Machine Learning for Developing a Biomarker Panel to Distinguish the Severity of Metabolic‐Associated Fatty Liver Disease
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Yanqiao Hui und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China. Hauptthemen laut MEDLINE: Biomarkers, Machine Learning, Metabolomics, Lipidomics. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Basic Scientific Research project of Higher Education Department of Liaoning Province, China Postdoctoral Science Foundation, Liaoning Provincial Applied Basic Research Project.
Abstract (Originalsprache)
Metabolic‐associated fatty liver disease (MAFLD), a global health challenge linked to metabolic syndrome, requires accurate severity stratification for clinical management. Current invasive diagnostic methods limit practical implementation. This study integrated multi‐omics and machine learning to establish a non‐invasive biomarker panel for the early stage of MAFLD assessment. Transcriptomic analysis of GEO datasets via weighted gene co‐expression network (WGCNA) and differential expression revealed critical pathways associated with MAFLD progression. Subsequently, LC–MS/MS‐based widely targeted metabolomics and lipidomics were conducted on plasma samples from 40 healthy controls and 120 patients with MAFLD at varying stages of severity (40 mild, 40 moderate, and 40 severe). Machine learning algorithms (LASSO regression, logistic regression, decision trees, and XGBoost) were then applied to these datasets to identify critical biomarkers linked to disease severity. Ultimately, a biomarker panel comprising 5‐aminolevulinic acid, mesaconic acid, shikimic acid, PC O‐35:3, and PI 36:2 exhibited outstanding diagnostic performance in detecting the prevalence and severity of MAFLD, achieving an accuracy of 88.3% in the training cohort and over 91.7% prediction accuracy in the independent test cohort. The identified biomarker panel offers a promising non‐invasive approach for assessing MAFLD severity, paving the way for precision medicine and treatment in MAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
- Department of Gastroenterology, The First Hospital of China Medical University, Shenyang, China.
Förderung
- Basic Scientific Research project of Higher Education Department of Liaoning Province
- China Postdoctoral Science Foundation
- Liaoning Provincial Applied Basic Research Project
Zitieren
APA
Hui, Y., Qu, J., Yang, J., Zhang, H., Liang, C., Miao, N., Zhang, Q., Xu, H., Li, Y., & Li, Q. (2025). Integration of Metabolomics, Lipidomics, and Machine Learning for Developing a Biomarker Panel to Distinguish the Severity of Metabolic‐Associated Fatty Liver Disease. Biomedical Chromatography. https://doi.org/10.1002/bmc.70142
Vancouver
Hui Y, Qu J, Yang J, Zhang H, Liang C, Miao N, et al. Integration of Metabolomics, Lipidomics, and Machine Learning for Developing a Biomarker Panel to Distinguish the Severity of Metabolic‐Associated Fatty Liver Disease. Biomedical Chromatography. 2025. doi:10.1002/bmc.70142
BibTeX
@article{Hui2025,
author = {Hui, Yanqiao and Qu, Jiameng and Yang, Junjie and Zhang, Hanwen and Liang, Chen and Miao, Naixin and Zhang, Qian and Xu, Huarong and Li, Yiling and Li, Qing},
title = {Integration of Metabolomics, Lipidomics, and Machine Learning for Developing a Biomarker Panel to Distinguish the Severity of Metabolic‐Associated Fatty Liver Disease},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70142}
}
EUVIMED